BioAge Labs reported second quarter 2026 financial results with a net loss of $26.1 million, or $0.58 per share, compared to a $21.6 million loss in the prior year period. Research and development expenses increased to $24.4 million from $19.8 million, driven by costs associated with the initiation of the Phase 2 QUELL-CV trial for BGE-102 and start-up activities for the planned Phase 1b/2a QUELL-DME trial in diabetic macular edema. The company generated $2.4 million in collaboration revenue and held approximately $381.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Clinically, BioAge dosed the first participant in QUELL-CV, a Phase 2 dose-ranging trial evaluating BGE-102 in patients with obesity and elevated cardiovascular risk, with topline data expected in the second half of 2026. The company also plans to initiate the QUELL-DME trial in mid-2026 to assess target engagement in ocular diseases. BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic and inflammatory diseases by targeting the biology of human aging.